Phaseline

Companies › Eilean Therapeutics

Eilean Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZE63-0302–Phase 1Type 2 DiabetesNov 2026
ZE94-0605
Selective cyclin-dependent kinase 2 (CDK2) inhibitor
CDK2Phase 1Advanced Solid Tumor CancerJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07234864ZE63-0302Phase 1Type 2 DiabetesMetabolic and endocrineNov 2026
NCT07524140ZE94-0605Phase 1Advanced Solid Tumor CancerOncologyJan 2028

Targets

CDK2 (1)

Companies with the same targets

NiKang Therapeutics Avenzo Therapeutics Chia Tai Tianqing Pharmaceutical Group BeiGene AstraZeneca Incyclix Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.